Pharma channel feed

As­traZeneca en­cour­ages NHL fans to get 'body checked' for can­cer

Last year
Marketing

FDA fi­nal­izes rule on us­ing mas­ter files in bi­o­log­ics ap­pli­ca­tions

Last year
FDA+

CSL and uniQure un­veil three-year da­ta for one-time he­mo­phil­ia B gene ther­a­py that costs $3.5M

Last year
R&D
Cell/Gene Tx

Sen­ate grills phar­ma CEOs, who emerge from hear­ing on drug prices large­ly un­scathed

Last year

House pass­es ban on use of QALYs in fed­er­al health pro­grams

Last year
FDA+

Ogilvy Health taps long­time WPP ex­ec Re­na­ta Ma­ia as chief cre­ative of­fi­cer

Last year
People
Marketing

Wall Street: GLP-1 com­peti­tors’ pain is Eli Lil­ly’s gain

Last year

As­traZeneca CEO calls open­ing IRA drug price of­fer 'rel­a­tive­ly en­cour­ag­ing' in first char­ac­ter­i­za­tion of talks

Last year
FDA+

Up­dat­ed: ‘Ruth­less’ pipeline pri­or­i­ti­za­tion, obe­si­ty and Chi­na: Three take­aways from As­traZeneca’s Q4 

Last year
China

House com­mit­tee plans hear­ing on Chi­nese biotech com­pe­ti­tion as ten­sions mount

Last year
China

New hear­ing, same blame game: Phar­ma, PBMs trade ac­cu­sa­tions ahead of Sen­ate ses­sion

Last year

Genen­tech is Broad­way bound with lat­est cam­paign to raise spinal mus­cu­lar at­ro­phy aware­ness

Last year
Marketing

House com­mit­tee ad­vances an­oth­er PBM re­form bill that would ban spread pric­ing

Last year
FDA+

As obe­si­ty mar­ket heats up, Am­gen leaves clues on Mar­i­Tide’s path for­ward

Last year

Up­dat­ed: Bridge­Bio inks $100M up­front deal with Ky­owa Kirin for skele­tal dis­or­der drug

Last year
Deals

Gilead won't ac­quire check­point on­col­o­gy biotech Tizona

Last year
Deals

Lil­ly to build man­u­fac­tur­ing ca­pac­i­ty at risk to pre­pare for next-gen oral obe­si­ty drug

Last year
Manufacturing

Gilead em­pha­sizes in­equities in HIV, hep C and can­cer through 'mar­gin' book project

Last year
Marketing

Law­mak­ers hold FDA for­eign in­spec­tion prac­tices un­der mi­cro­scope at hear­ing with­out agency at­ten­dance

Last year
FDA+
Manufacturing

Will an up­com­ing Sen­ate hear­ing help low­er drug prices? It de­pends who you ask

Last year
FDA+

Uni­ver­si­ties de­cry Biden's plan for 'march-in' rights as dis­in­cen­tiviz­ing bio­phar­ma part­ner­ships

Last year
Law

J&J em­ploy­ee sues com­pa­ny over al­leged mis­man­age­ment of pre­scrip­tion drug pro­gram

Last year
Law

Mar­ket­ingRx roundup: Phar­ma mar­keters grab screen time at Gram­my Awards; Boehringer adds new Jar­diance TV ad

Last year
Marketing

Phar­ma ads get caught by stricter Meta en­force­ment in elec­tion year

Last year
Marketing
First page Previous page 74757677787980 Next page Last page
A service from the Financial Times